RU2006145886A - Производные метастина и их применение - Google Patents
Производные метастина и их применение Download PDFInfo
- Publication number
- RU2006145886A RU2006145886A RU2006145886/04A RU2006145886A RU2006145886A RU 2006145886 A RU2006145886 A RU 2006145886A RU 2006145886/04 A RU2006145886/04 A RU 2006145886/04A RU 2006145886 A RU2006145886 A RU 2006145886A RU 2006145886 A RU2006145886 A RU 2006145886A
- Authority
- RU
- Russia
- Prior art keywords
- trp
- arg
- phe
- group
- leu
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 87
- 125000000217 alkyl group Chemical group 0.000 claims 46
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 claims 35
- 150000003839 salts Chemical class 0.000 claims 35
- 239000000651 prodrug Substances 0.000 claims 29
- 229940002612 prodrug Drugs 0.000 claims 29
- 125000004432 carbon atom Chemical group C* 0.000 claims 27
- 125000001424 substituent group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- 229910052760 oxygen Inorganic materials 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 19
- -1 glyoxyloyl Chemical group 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 16
- 238000011282 treatment Methods 0.000 claims 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 13
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 13
- 125000004122 cyclic group Chemical group 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Chemical group 0.000 claims 12
- 230000028327 secretion Effects 0.000 claims 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 229940127557 pharmaceutical product Drugs 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 125000004434 sulfur atom Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000003163 gonadal steroid hormone Substances 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 108010086677 Gonadotropins Proteins 0.000 claims 8
- 102000006771 Gonadotropins Human genes 0.000 claims 8
- 239000002622 gonadotropin Substances 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 230000002159 abnormal effect Effects 0.000 claims 6
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 239000005556 hormone Substances 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 238000009833 condensation Methods 0.000 claims 4
- 230000005494 condensation Effects 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010000234 Abortion spontaneous Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims 3
- 201000009273 Endometriosis Diseases 0.000 claims 3
- 102000003839 Human Proteins Human genes 0.000 claims 3
- 108090000144 Human Proteins Proteins 0.000 claims 3
- 102100034845 KiSS-1 receptor Human genes 0.000 claims 3
- 101710104293 KiSS-1 receptor Proteins 0.000 claims 3
- 108010012048 Kisspeptins Proteins 0.000 claims 3
- 102000013599 Kisspeptins Human genes 0.000 claims 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 230000004153 glucose metabolism Effects 0.000 claims 3
- 230000002710 gonadal effect Effects 0.000 claims 3
- 208000000509 infertility Diseases 0.000 claims 3
- 230000036512 infertility Effects 0.000 claims 3
- 231100000535 infertility Toxicity 0.000 claims 3
- 201000010260 leiomyoma Diseases 0.000 claims 3
- 230000037356 lipid metabolism Effects 0.000 claims 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims 3
- 208000015994 miscarriage Diseases 0.000 claims 3
- 230000016087 ovulation Effects 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- 208000000995 spontaneous abortion Diseases 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims 2
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- GZYFIMLSHBLMKF-UHFFFAOYSA-N ALBIZZIINE Chemical compound OC(=O)C(N)CNC(N)=O GZYFIMLSHBLMKF-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000002826 placenta Anatomy 0.000 claims 2
- 208000006155 precocious puberty Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000005750 substituted cyclic group Chemical group 0.000 claims 2
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 claims 1
- PDRJLZDUOULRHE-SSDOTTSWSA-N (2r)-2-azaniumyl-3-pyridin-2-ylpropanoate Chemical compound OC(=O)[C@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-SSDOTTSWSA-N 0.000 claims 1
- FQFVANSXYKWQOT-SSDOTTSWSA-N (2r)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-SSDOTTSWSA-N 0.000 claims 1
- RWLSBXBFZHDHHX-VIFPVBQESA-N (2s)-2-(naphthalen-2-ylamino)propanoic acid Chemical compound C1=CC=CC2=CC(N[C@@H](C)C(O)=O)=CC=C21 RWLSBXBFZHDHHX-VIFPVBQESA-N 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- RFRJUFFMYCMGHN-UHFFFAOYSA-N 2,2-diamino-4-oxobutanoic acid Chemical compound OC(=O)C(N)(N)CC=O RFRJUFFMYCMGHN-UHFFFAOYSA-N 0.000 claims 1
- ZIPUIDBGTLUSKQ-UHFFFAOYSA-N 2,2-diamino-4-oxopentanoic acid Chemical compound CC(=O)CC(N)(N)C(O)=O ZIPUIDBGTLUSKQ-UHFFFAOYSA-N 0.000 claims 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 1
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 108010041505 gonadotropin inhibitor Proteins 0.000 claims 1
- 125000003651 hexanedioyl group Chemical group C(CCCCC(=O)*)(=O)* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003169 placental effect Effects 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004-187671 | 2004-06-25 | ||
| JP2004187671 | 2004-06-25 | ||
| JP2004363311 | 2004-12-15 | ||
| JP2004-363311 | 2004-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006145886A true RU2006145886A (ru) | 2008-06-27 |
Family
ID=34971534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006145886/04A RU2006145886A (ru) | 2004-06-25 | 2005-06-23 | Производные метастина и их применение |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7625869B2 (enExample) |
| EP (2) | EP2113513B1 (enExample) |
| JP (3) | JP4346650B2 (enExample) |
| CN (2) | CN101863971A (enExample) |
| AR (1) | AR049938A1 (enExample) |
| AU (1) | AU2005257484A1 (enExample) |
| BR (1) | BRPI0512397A (enExample) |
| CA (1) | CA2571420A1 (enExample) |
| CL (1) | CL2008003730A1 (enExample) |
| CR (1) | CR8828A (enExample) |
| IL (1) | IL179640A0 (enExample) |
| MA (1) | MA28903B1 (enExample) |
| MX (1) | MXPA06014206A (enExample) |
| NO (1) | NO20065957L (enExample) |
| NZ (1) | NZ552029A (enExample) |
| PE (2) | PE20060371A1 (enExample) |
| RU (1) | RU2006145886A (enExample) |
| SG (1) | SG153865A1 (enExample) |
| TW (1) | TW200607816A (enExample) |
| WO (1) | WO2006001499A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8765909B2 (en) | 2006-10-25 | 2014-07-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8778871B2 (en) | 2004-06-25 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1494732B1 (en) | 2002-03-20 | 2008-01-30 | MannKind Corporation | Inhalation apparatus |
| EP1604682A4 (en) | 2003-03-12 | 2009-06-24 | Takeda Chemical Industries Ltd | AGENTS IMPROVING GONADIC FUNCTION |
| AU2005245338B2 (en) | 2004-04-08 | 2011-11-17 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| US8183212B2 (en) * | 2006-04-26 | 2012-05-22 | Kyoto University | Compound having GPR54 agonistic activity |
| ITMI20061607A1 (it) * | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| CN101528772B (zh) * | 2006-10-25 | 2013-03-13 | 武田药品工业株式会社 | Metastin衍生物及其用途 |
| EP2277900A4 (en) * | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| EP2275433B1 (en) * | 2008-04-30 | 2017-06-07 | Kyoto University | Metastin derivative and use thereof |
| SG10201507036TA (en) | 2008-06-13 | 2015-10-29 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| US20110212890A1 (en) * | 2008-07-30 | 2011-09-01 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| CA2748517A1 (en) * | 2008-12-29 | 2010-07-08 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8716228B2 (en) | 2009-05-27 | 2014-05-06 | Yeda Research And Development Co. Ltd. | GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities |
| UY33127A (es) | 2009-12-22 | 2011-07-29 | Takeda Pharmaceutical | Formulación de liberación sostenida |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| EP2694402B1 (en) | 2011-04-01 | 2017-03-22 | MannKind Corporation | Blister package for pharmaceutical cartridges |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| US9127038B2 (en) | 2011-08-04 | 2015-09-08 | Merck Sharp & Dohme Corp. | Kisspeptide-pentasaccharide conjugates |
| HK1200318A1 (en) | 2011-10-24 | 2015-08-07 | 曼金德公司 | Methods and compositions for treating pain |
| JP2015511600A (ja) | 2012-03-14 | 2015-04-20 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | 修飾キスペプチンペプチドおよびその使用 |
| EP2872205B1 (en) | 2012-07-12 | 2017-02-08 | MannKind Corporation | Dry powder drug delivery systems |
| EP3249054A1 (en) | 2012-12-20 | 2017-11-29 | Biomatrica, INC. | Formulations and methods for stabilizing pcr reagents |
| JP6143270B2 (ja) * | 2013-01-31 | 2017-06-07 | 学校法人東京薬科大学 | マイオスタチン阻害ペプチド |
| KR102465025B1 (ko) | 2013-07-18 | 2022-11-09 | 맨카인드 코포레이션 | 열-안정성 건조 분말 약제학적 조성물 및 방법 |
| US10220069B2 (en) * | 2014-01-22 | 2019-03-05 | The Johns Hopkins University | Compositions and methods for treating diabetes |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
| KR102589056B1 (ko) | 2015-12-08 | 2023-10-12 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| MA46353A (fr) | 2016-09-30 | 2019-08-07 | Myovant Sciences Gmbh | Méthodes de traitement de l'infertilité féminine |
| CN109206481B (zh) | 2017-07-05 | 2023-08-18 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| CN108752233B (zh) * | 2018-07-18 | 2020-10-16 | 河北师范大学 | 小分子凝胶因子、凝胶材料及制备方法和应用 |
| CN115515937A (zh) * | 2020-05-08 | 2022-12-23 | 范因斯坦医学研究院 | 用于合成肽模拟物的二聚体 |
| WO2025217074A1 (en) | 2024-04-08 | 2025-10-16 | Radionetics Oncology, Inc. | Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1524747A (en) * | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| FR2488253A1 (fr) * | 1980-08-08 | 1982-02-12 | Roques Bernard | Nouveaux peptides et leur application en therapeutique |
| IL74827A (en) * | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
| MX9100717A (es) * | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| AU7333496A (en) | 1995-10-19 | 1997-05-07 | Takeda Chemical Industries Ltd. | Quinoline derivatives as gnrh antagonists |
| JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
| AU2382097A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP4486187B2 (ja) | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| HK1047045A1 (zh) | 1999-06-28 | 2003-02-07 | Abbott Gmbh & Co. Kg | 預防腫瘤生長的方法 |
| US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| WO2001044469A1 (fr) | 1999-12-17 | 2001-06-21 | Takeda Chemical Industries, Ltd. | PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1 |
| JP2001231581A (ja) * | 1999-12-17 | 2001-08-28 | Takeda Chem Ind Ltd | ＫｉＳＳ−１ペプチドの製造法 |
| HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
| CA2404257A1 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Novel protein, dna thereof and process for producing the same |
| US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
| JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| US20040185525A1 (en) * | 2001-05-17 | 2004-09-23 | Osamu Nishimura | Process for producing peptide |
| ATE360034T1 (de) * | 2001-09-19 | 2007-05-15 | Takeda Pharmaceutical | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft |
| EP1466976A4 (en) | 2002-01-11 | 2005-11-09 | Takeda Pharmaceutical | PROCESS FOR PREPARING KISS-1 PEPTIDES |
| JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
| US20060035875A1 (en) | 2002-10-09 | 2006-02-16 | Yukimasa Shiotsu | Remedy for hormone-dependent cancer |
| CA2503164A1 (en) | 2002-10-25 | 2004-05-06 | Paradigm Therapeutics Limited | Gpr54 knock-out mammals and screening methods using them |
| JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| AU2003292696A1 (en) | 2002-12-26 | 2004-08-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| US6800611B2 (en) | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
| KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Ｌｋ8 단백질을 유효성분으로 포함하는 항암제 |
| EP1604682A4 (en) | 2003-03-12 | 2009-06-24 | Takeda Chemical Industries Ltd | AGENTS IMPROVING GONADIC FUNCTION |
| EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| CA2523600A1 (en) | 2003-04-28 | 2004-11-11 | Wyeth | Methods utilising g-protein coupled receptor 54 |
| WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
| US20070155803A1 (en) | 2003-05-30 | 2007-07-05 | Prozymex A/S | Protease inhibitors |
| JP4688678B2 (ja) | 2003-11-03 | 2011-05-25 | 北京沙東生物技術有限公司 | 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 |
| RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
| WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
| CA2562676A1 (en) | 2004-04-23 | 2005-12-15 | Applied Research Systems Ars Holding N.V. | Use of gpcr54 ligands for the treatment of infertility |
| MXPA06014206A (es) | 2004-06-25 | 2007-02-14 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos. |
| WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
| US20090099334A1 (en) | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090093615A1 (en) | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JP2009530379A (ja) | 2006-03-20 | 2009-08-27 | メルク エンド カムパニー インコーポレーテッド | ニューロメジンｕ受容体アゴニスト及びその使用 |
| WO2007109857A1 (en) | 2006-03-28 | 2007-10-04 | Biopharmica Ltd | Agent for the treatment of hormone-dependent disorders and uses thereof |
| TWI404726B (zh) | 2006-10-25 | 2013-08-11 | Takeda Pharmaceutical | 腫瘤轉移抑制素衍生物及其用途 |
| WO2009044918A1 (ja) | 2007-10-05 | 2009-04-09 | Takeda Pharmaceutical Company Limited | ニューロメジンｕ誘導体 |
| EP2277900A4 (en) | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| EP2340047A1 (en) | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
-
2005
- 2005-06-23 MX MXPA06014206A patent/MXPA06014206A/es unknown
- 2005-06-23 AU AU2005257484A patent/AU2005257484A1/en not_active Abandoned
- 2005-06-23 BR BRPI0512397-6A patent/BRPI0512397A/pt not_active IP Right Cessation
- 2005-06-23 RU RU2006145886/04A patent/RU2006145886A/ru not_active Application Discontinuation
- 2005-06-23 JP JP2006554374A patent/JP4346650B2/ja not_active Expired - Fee Related
- 2005-06-23 PE PE2005000728A patent/PE20060371A1/es not_active Application Discontinuation
- 2005-06-23 PE PE2009000637A patent/PE20091567A1/es not_active Application Discontinuation
- 2005-06-23 AR ARP050102591A patent/AR049938A1/es unknown
- 2005-06-23 WO PCT/JP2005/012021 patent/WO2006001499A2/en not_active Ceased
- 2005-06-23 US US11/630,698 patent/US7625869B2/en not_active Expired - Fee Related
- 2005-06-23 SG SG200904360-5A patent/SG153865A1/en unknown
- 2005-06-23 EP EP09075257.7A patent/EP2113513B1/en not_active Expired - Lifetime
- 2005-06-23 CN CN200910225194A patent/CN101863971A/zh active Pending
- 2005-06-23 TW TW094120917A patent/TW200607816A/zh unknown
- 2005-06-23 EP EP05755666A patent/EP1758932A2/en not_active Withdrawn
- 2005-06-23 NZ NZ552029A patent/NZ552029A/en not_active IP Right Cessation
- 2005-06-23 CA CA002571420A patent/CA2571420A1/en not_active Abandoned
- 2005-06-23 CN CN200910225195A patent/CN101845091A/zh active Pending
-
2006
- 2006-11-27 IL IL179640A patent/IL179640A0/en unknown
- 2006-12-21 NO NO20065957A patent/NO20065957L/no not_active Application Discontinuation
- 2006-12-22 CR CR8828A patent/CR8828A/es not_active Application Discontinuation
- 2006-12-28 MA MA29567A patent/MA28903B1/fr unknown
-
2008
- 2008-09-25 JP JP2008245073A patent/JP4654284B2/ja not_active Expired - Fee Related
- 2008-10-01 US US12/286,671 patent/US8778871B2/en active Active
- 2008-12-15 CL CL2008003730A patent/CL2008003730A1/es unknown
-
2009
- 2009-06-01 JP JP2009132363A patent/JP2009227687A/ja active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8778871B2 (en) | 2004-06-25 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| RU2430107C2 (ru) * | 2005-12-22 | 2011-09-27 | Такеда Фармасьютикал Компани Лимитед | Производные метастина и их применение |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8765909B2 (en) | 2006-10-25 | 2014-07-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US8778871B2 (en) | 2014-07-15 |
| SG153865A1 (en) | 2009-07-29 |
| US7625869B2 (en) | 2009-12-01 |
| MXPA06014206A (es) | 2007-02-14 |
| CN101845091A (zh) | 2010-09-29 |
| EP2113513A2 (en) | 2009-11-04 |
| BRPI0512397A (pt) | 2008-03-04 |
| CR8828A (es) | 2007-07-19 |
| PE20060371A1 (es) | 2006-06-15 |
| JP2009227687A (ja) | 2009-10-08 |
| EP2113513B1 (en) | 2016-05-18 |
| WO2006001499A2 (en) | 2006-01-05 |
| NO20065957L (no) | 2007-01-25 |
| US20080312155A1 (en) | 2008-12-18 |
| AU2005257484A1 (en) | 2006-01-05 |
| CL2008003730A1 (es) | 2009-05-04 |
| PE20091567A1 (es) | 2009-11-03 |
| JP4654284B2 (ja) | 2011-03-16 |
| AR049938A1 (es) | 2006-09-13 |
| WO2006001499A3 (en) | 2006-03-02 |
| JP2009024028A (ja) | 2009-02-05 |
| US20090298765A1 (en) | 2009-12-03 |
| TW200607816A (en) | 2006-03-01 |
| IL179640A0 (en) | 2007-05-15 |
| EP2113513A3 (en) | 2010-11-03 |
| NZ552029A (en) | 2009-01-31 |
| JP2008506632A (ja) | 2008-03-06 |
| CN101863971A (zh) | 2010-10-20 |
| EP1758932A2 (en) | 2007-03-07 |
| CA2571420A1 (en) | 2006-01-05 |
| JP4346650B2 (ja) | 2009-10-21 |
| MA28903B1 (fr) | 2007-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009024028A5 (enExample) | ||
| JP2010507565A5 (enExample) | ||
| Trackman et al. | Cloning of rat aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence | |
| JP4346650B2 (ja) | メタスチン誘導体およびその用途 | |
| US6228840B1 (en) | Melanocortin receptor antagonists and modulations of melanocortin receptor activity | |
| BRPI0717441B1 (pt) | Composto, medicamento, e, uso do derivado de metastina | |
| BR112016008331B1 (pt) | Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp | |
| RU2008125063A (ru) | Производные метастина и их применение | |
| BRPI0012688B1 (pt) | Método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas | |
| TW201114434A (en) | Oxytocin receptor agonists | |
| US7732412B2 (en) | Methods of treatment using novel LHRH antagonists having improved solubility properties | |
| TW200412995A (en) | Peptide YY analogs | |
| HUT77979A (hu) | Peptidek, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| US20160184426A9 (en) | Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response | |
| WO2020230780A1 (ja) | Ｒａｓ阻害ペプチド | |
| JP2002502381A (ja) | 環状ｃｒｆアンタゴニストペプチド | |
| TWI242441B (en) | Pharmaceutical composition comprising cyclic somatostatin analogs | |
| CN110678550A (zh) | 长效肾上腺髓质素衍生物 | |
| WO2010022639A1 (zh) | 靶特异性双突变体融合蛋白质 | |
| US6156725A (en) | Drug for the treatment of cancer | |
| JP6100699B2 (ja) | 環状ｃｒｆアンタゴニストペプチド及びその薬学的に許容される塩 | |
| RU2009119507A (ru) | Производные метастина и их применение | |
| JPH11510147A (ja) | 成長ホルモンに対する阻害活性をもつソマトスタチン類似環状ペプチド | |
| CA2005420C (en) | Competitive gonadoliberin antagonists | |
| RU2792364C1 (ru) | Пептид, обладающий активностью белка slurp-1 человека, и его применение для подавления роста карцином и глиом, фармацевтическая композиция для подавления роста карцином и глиом, и способ подавления роста карцином и глиом с использованием указанного пептида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101113 |